42
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumor cells must generate sufficient ATP and biosynthetic precursors in order to maintain cell proliferation requirements. Otto Warburg showed that tumor cells uptake high amounts of glucose producing large volumes of lactate even in the presence of oxygen, this process is known as “Warburg effect or aerobic glycolysis.” As a consequence of such amounts of lactate there is an acidification of the extracellular pH in tumor microenvironment, ranging between 6.0 and 6.5. This acidosis favors processes such as metastasis, angiogenesis and more importantly, immunosuppression, which has been associated to a worse clinical prognosis. Thus, lactate should be thought as an important oncometabolite in the metabolic reprogramming of cancer. In this review, we summarized the role of lactate in regulating metabolic microenvironment of cancer and discuss its relevance in the up-regulation of the enzymes lactate dehydrogenase (LDH) and monocarboxilate transporters (MCTs) in tumors. The goal of this review is to expose that lactate is not only a secondary product of cellular metabolic waste of tumor cells, but also a key molecule involved in carcinogenesis as well as in tumor immune evasion. Finally, the possible targeting of lactate production in cancer treatment is discussed.

          Related collections

          Most cited references142

          • Record: found
          • Abstract: found
          • Article: not found

          LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

          Elevated lactate dehydrogenase A (LDHA) expression is associated with poor outcome in tumor patients. Here we show that LDHA-associated lactic acid accumulation in melanomas inhibits tumor surveillance by T and NK cells. In immunocompetent C57BL/6 mice, tumors with reduced lactic acid production (Ldha(low)) developed significantly slower than control tumors and showed increased infiltration with IFN-γ-producing T and NK cells. However, in Rag2(-/-)γc(-/-) mice, lacking lymphocytes and NK cells, and in Ifng(-/-) mice, Ldha(low) and control cells formed tumors at similar rates. Pathophysiological concentrations of lactic acid prevented upregulation of nuclear factor of activated T cells (NFAT) in T and NK cells, resulting in diminished IFN-γ production. Database analyses revealed negative correlations between LDHA expression and T cell activation markers in human melanoma patients. Our results demonstrate that lactic acid is a potent inhibitor of function and survival of T and NK cells leading to tumor immune escape.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Up on the tightrope: natural killer cell activation and inhibition.

            Natural killer (NK) cells circulate through the blood, lymphatics and tissues, on patrol for the presence of transformed or pathogen-infected cells. As almost all NK cell receptors bind to host-encoded ligands, signals are constantly being transmitted into NK cells, whether they interact with normal or abnormal cells. The sophisticated repertoire of activating and inhibitory receptors that has evolved to regulate NK cell activity ensures that NK cells protect hosts against pathogens, yet prevents deleterious NK cell-driven autoimmune responses. Here I highlight recent advances in our understanding of the structural properties and signaling pathways of the inhibitory and activating NK cell receptors, with a particular focus on the ITAM-dependent activating receptors, the NKG2D-DAP10 receptor complexes and the CD244 receptor system.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Lactate Metabolism in Human Lung Tumors

              Cancer cells consume glucose and secrete lactate in culture. It is unknown whether lactate contributes to energy metabolism in living tumors. We previously reported that human non-small cell lung cancers (NSCLC) oxidize glucose in the tricarboxylic acid (TCA) cycle. Here we show that lactate is also a TCA cycle carbon source for NSCLC. In human NSCLC, evidence of lactate utilization was most apparent in tumors with high 18 fluorodeoxyglucose uptake and aggressive oncological behavior. Infusing human NSCLC patients with 13 C-lactate revealed extensive labeling of TCA cycle metabolites. In mice, deleting monocarboxylate transporter-1 (MCT1) from tumor cells eliminated lactate-dependent metabolite labeling, confirming tumor-cell autonomous lactate uptake. Strikingly, directly comparing lactate and glucose metabolism in vivo indicated that lactate's contribution to the TCA cycle predominates. The data indicate that tumors, including bona fide human NSCLC, can use lactate as a fuel in vivo. Human non-small cell lung cancer preferentially utilizes lactate over glucose to fuel TCA cycle and sustain tumor metabolism in vivo.
                Bookmark

                Author and article information

                Contributors
                URI : http://loop.frontiersin.org/people/811051/overview
                URI : http://loop.frontiersin.org/people/832491/overview
                URI : http://loop.frontiersin.org/people/722732/overview
                Journal
                Front Oncol
                Front Oncol
                Front. Oncol.
                Frontiers in Oncology
                Frontiers Media S.A.
                2234-943X
                01 November 2019
                2019
                : 9
                : 1143
                Affiliations
                [1] 1Programa de Doctorado en Ciencias Biomédicas, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria , Mexico City, Mexico
                [2] 2Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, México/Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México , Mexico City, Mexico
                [3] 3Laboratory of Virus and Cancer, Subdirección de Investigación Básica, Instituto Nacional de Cancerología , Mexico City, Mexico
                [4] 4Programa de Maestría y Doctorado en Ciencias Médicas, Odontológicas y de la Salud, Maestría en Investigación Clínica Experimental, Universidad Nacional Autónoma de Mexico , Mexico City, Mexico
                [5] 5Biological Cancer Causing Agents Group, Instituto Nacional de Cancerología , Mexico City, Mexico
                [6] 6Cátedras CONACyT-Instituto Nacional de Cancerología , Mexico City, Mexico
                Author notes

                Edited by: Nadia Judith Jacobo-Herrera, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico

                Reviewed by: Michael P. Lisanti, University of Salford, United Kingdom; Liwei Lang, Augusta University, United States

                *Correspondence: Joaquín Manzo-Merino jmanzome@ 123456conacyt.mx

                This article was submitted to Cancer Metabolism, a section of the journal Frontiers in Oncology

                Article
                10.3389/fonc.2019.01143
                6839026
                31737570
                0a196da3-1be1-4710-82ca-dfb1f1700cd6
                Copyright © 2019 de la Cruz-López, Castro-Muñoz, Reyes-Hernández, García-Carrancá and Manzo-Merino.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 17 August 2019
                : 15 October 2019
                Page count
                Figures: 4, Tables: 2, Equations: 0, References: 192, Pages: 21, Words: 16613
                Categories
                Oncology
                Review

                Oncology & Radiotherapy
                lactate,acidification,tumor microenvironment (tme),therapy,immune response
                Oncology & Radiotherapy
                lactate, acidification, tumor microenvironment (tme), therapy, immune response

                Comments

                Comment on this article